Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Vaccine hopes boost world share markets

share with twitter share with LinkedIn share with facebook
09/14/2020 | 04:34am EDT

* AstraZeneca resumes phase-3 trial for coronavirus vaccine

* UK, US, Japan central banks meet this week

* Japan's Suga wins ruling party leadership race

* UK parliament to vote on plan to break Brexit divorce treaty

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

LONDON, Sept 14 (Reuters) - World stocks rallied on Monday on hopes for a coronavirus vaccine after AstraZeneca resumed its phase-3 trial, but caution lingered before a host of central bank meetings this week.

Sterling, which has been hit by renewed Brexit turmoil, was on firmer ground before a vote on British Prime Minister Boris Johnson's plan to break international law by breaching parts of the Brexit divorce treaty with the European Union.

European stock markets opened broadly higher and U.S. stock futures rallied more than 1% -- suggesting a strong start for Wall Street later on.

In Asia, MSCI's broadest index of Asia-Pacific shares outside Japan rose 0.9% to its highest in almost a week. Japan's Nikkei firmed 0.7% after Chief Cabinet Secretary Yoshihide Suga won a landslide victory in a ruling party leadership election, paving the way for him to succeed Prime Minister Shinzo Abe.

Drugmaker AstraZeneca said at the weekend it has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

The news provided a boost to sentiment in world share markets, hit last week by a selloff in U.S. tech stocks.

"The news over the weekend that AstraZeneca clinical trials had resumed is likely to be well received, however it is unlikely to assuage concerns that the speed with which these trials are being done could result in a vaccine being rushed out too hastily, with unforeseen circumstances," said Michael Hewson, chief market analyst at CMC Markets UK.

U.S. chipmaker Nvidia Corp said it would buy UK-based chip designer Arm from Japan's SoftBank Group for as much as $40 billion in a deal set to reshape the global semiconductor landscape, spurring a 1% gain in Europe's tech sector.

Friday marked six months since the World Health Organization (WHO) declared the coronavirus a pandemic on March 11.

Since then, major global economies have slipped into recession and millions have lost their jobs, prompting central banks around the world to launch unprecedented stimulus.

The U.S. Federal Reserve this week holds a two-day policy meeting and is expected to hold rates while elaborating on an earlier announcement of a shift to inflation targeting. The Bank of Japan and the Bank of England will announce their respective policy decisions on Thursday.


Major currencies were stable on Monday, with the British pound holding above 1-1/2 month lows against the dollar ahead of a parliamentary debate on the Internal Market Bill. After the debate, lawmakers will vote to decide if it should go to the next stage.

Johnson's decision to explicitly break international law has plunged Brexit back into crisis less than four months before Britain is finally due to leave the EU's orbit at the end of a post-Brexit transition period.

"The question will be how many Conservative MPs (members of parliament) rebel on the matter," said Deutsche Bank strategist Jim Reid, referring to Johnson's ruling party.

The dollar was a tad weaker at 106 yen, though still a long distance from its low this year of 101.2. The euro was a touch firmer at $1.1857.

In commodities, U.S. crude jumped 0.6% to $37.55 a barrel. Brent crude climbed 0.4% to $40 per barrel.

Gold was firm, with spot prices at $1,946.9 per ounce.

Elsewhere, Turkey's currency and dollar-bonds came under pressure after Moody's cut the country's sovereign rating and warned of the risk of a balance of payment crisis. The lira weakened 0.2%, flirting with fresh record lows last week.

(Reporting by Dhara Ranasinghe;Additional reporting by Swati Pandey in Sydney; Editing by Peter Graff)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.11% 7920 Delayed Quote.4.11%
CMC MARKETS PLC 0.15% 337 Delayed Quote.129.88%
DEUTSCHE BANK AG -2.39% 7.955 Delayed Quote.15.01%
EURO / BRITISH POUND (EUR/GBP) -0.07% 0.902 Delayed Quote.7.96%
LONDON BRENT OIL 0.24% 41.7 Delayed Quote.-35.68%
NIKKEI 225 -0.70% 23474.27 Real-time Quote.-0.38%
NVIDIA CORPORATION -0.88% 540.99 Delayed Quote.129.92%
SOFTBANK GROUP CORP. -0.71% 7089 End-of-day quote.49.05%
WTI 0.26% 39.957 Delayed Quote.-32.53%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:20aBritain partners with Oxford firm to assess coronavirus vaccine T cell respon..
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
10/21ASTRAZENECA : Operation Warp Speed Chief Slaoui Expects U.S. Trials Of Vaccines ..
10/21Ecuador signs COVID-19 vaccine supply deals with pharma companies
10/21ASTRAZENECA : Volunteer in AstraZeneca/Oxford Coronavirus Vaccine Trial Dies in ..
10/21ASTRAZENECA : Deceased Astrazeneca Trial Volunteer Didn't Receive The Vaccine So..
10/21AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue
10/21Brazil's Bolsonaro rejects plan to buy China's Sinovac vaccine; health minist..
10/21ASTRAZENECA : advances leadership in renal disease with more than 80 abstracts a..
10/21SANOFI : EU signs supply deal with J&J on potential COVID-19 vaccine
More news
Financials (USD)
Sales 2020 26 717 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 47,6x
Yield 2020 2,71%
Capitalization 136 B 137 B -
EV / Sales 2020 5,60x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 117,90 $
Last Close Price 103,98 $
Spread / Highest target 49,5%
Spread / Average Target 13,4%
Spread / Lowest Target -36,5%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-1.33%380 575
ROCHE HOLDING AG-2.21%289 156
PFIZER INC.-4.31%208 327
MERCK & CO., INC.-14.16%197 964
NOVARTIS AG-15.38%188 853